<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943211</url>
  </required_header>
  <id_info>
    <org_study_id>HISTIOGEN.</org_study_id>
    <nct_id>NCT04943211</nct_id>
  </id_info>
  <brief_title>Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis</brief_title>
  <acronym>HISTIOGEN</acronym>
  <official_title>Determination of Molecular Status, as Well as the Efficacy and Safety of Fluorodeoxyglucose (18F-FDG) in PET-CT Imaging in Juvenile Patients With Histiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Raciborska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Łukasiewicz Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wrocław University of Environmental and Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Mother and Child, Warsaw, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, low intervention, open, single-center, non-commercial clinical trial to improve&#xD;
      diagnostics in patients with histiocytosis by assessing the molecular profile of the tumor&#xD;
      tissues, monitoring its presence in free-circulating DNA, and determining the efficacy of&#xD;
      fluorodeoxyglucose (18F-FDG) in PET-CT imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HISTIOGEN clinical study is part of the POL HISTIO project. The POL HISTIO project is a&#xD;
      non-commercial clinical trial aimed at optimizing the diagnosis and treatment of juvenile&#xD;
      patients with histiocytosis. The project objectives are defined as follows: 1) to estimate&#xD;
      the nature and frequency of mutations in patients with histiocytosis in both tumor tissues&#xD;
      and free-circulating DNA; 2) to compare molecular test results with clinical data; 3) to&#xD;
      evaluate the diagnostic usefulness of the status of molecular analysis (MRD) as a prognostic&#xD;
      factor compared with other recognized factors. As part of the HISTIOGEN protocol, an&#xD;
      immortalized cell line will be derived to study the pathogenesis of the disease, drug&#xD;
      sensitivity, and drug resistance mechanisms. The project is intended to include patients from&#xD;
      all over Poland&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 23, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>EFS - (event-free survival)</measure>
    <time_frame>2 years</time_frame>
    <description>Event-free survival (EFS) was defined as the time interval from the date of diagnosis to the date of disease progression, recurrence, second malignancy, death or to date of last follow-up for patients without events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS (Overall Survival)</measure>
    <time_frame>2 years</time_frame>
    <description>Overall Survival (OS) was defined as the time interval from the date of diagnosis to the date of death or to last follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular relapse (in ct DNA)</measure>
    <time_frame>2 years</time_frame>
    <description>Molecular relapse was defined as the time interval from the date of any mutation negativization to the date of positive results of any mutation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Histiocytosis</condition>
  <arm_group>
    <arm_group_label>R1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorodeoxyglucose (18F-FDG)</intervention_name>
    <description>max 6 MGBq/kg, no more than 100</description>
    <arm_group_label>R1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient under 18 years of age at the time of inclusion.&#xD;
&#xD;
          2. Histopatologically confirmed or suspected histiocytosis (based on prior test results).&#xD;
&#xD;
          3. Signing of informed consent for trial participation according with current legal&#xD;
             regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of inclusion criteria.&#xD;
&#xD;
          2. Pregnancy.&#xD;
&#xD;
          3. Other acute or persistent disorders, behaviors or abnormal laboratory test results,&#xD;
             which might increase the risk related to the participation in this clinical trial or&#xD;
             to taking the study drug, or which might influence the interpretation of the study&#xD;
             results, or which, in the investigator's opinion, disqualify a patient from&#xD;
             participating in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Raciborska</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mother and Child Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna Maleszewska</last_name>
    <phone>+48 22 32 77 205</phone>
    <email>klinika.onkologii@imid.med.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mother and Child Institute</name>
      <address>
        <city>Warsaw</city>
        <state>Mazovian</state>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Maleszewska</last_name>
      <phone>+48 22 32 77 205</phone>
      <email>klinika.onkologii@imid.med.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Raciborska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Abla O, Jacobsen E, Picarsic J, Krenova Z, Jaffe R, Emile JF, Durham BH, Braier J, Charlotte F, Donadieu J, Cohen-Aubart F, Rodriguez-Galindo C, Allen C, Whitlock JA, Weitzman S, McClain KL, Haroche J, Diamond EL. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018 Jun 28;131(26):2877-2890. doi: 10.1182/blood-2018-03-839753. Epub 2018 May 2. Review.</citation>
    <PMID>29720485</PMID>
  </reference>
  <reference>
    <citation>Andersson D, Fagman H, Dalin MG, Ståhlberg A. Circulating cell-free tumor DNA analysis in pediatric cancers. Mol Aspects Med. 2020 Apr;72:100819. doi: 10.1016/j.mam.2019.09.003. Epub 2019 Sep 25. Review.</citation>
    <PMID>31563277</PMID>
  </reference>
  <reference>
    <citation>Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010 Sep 16;116(11):1919-23. doi: 10.1182/blood-2010-04-279083. Epub 2010 Jun 2.</citation>
    <PMID>20519626</PMID>
  </reference>
  <reference>
    <citation>Donadieu J, Piguet C, Bernard F, Barkaoui M, Ouache M, Bertrand Y, Ibrahim H, Emile JF, Hermine O, Tazi A, Genereau T, Thomas C. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004 Dec;43(7):770-6.</citation>
    <PMID>15390280</PMID>
  </reference>
  <reference>
    <citation>Fanti S, Franchi R, Battista G, Monetti N, Canini R. PET and PET-CT. State of the art and future prospects. Radiol Med. 2005 Jul-Aug;110(1-2):1-15. Review. English, Italian.</citation>
    <PMID>16163136</PMID>
  </reference>
  <reference>
    <citation>Goyal G, Heaney ML, Collin M, Cohen-Aubart F, Vaglio A, Durham BH, Hershkovitz-Rokah O, Girschikofsky M, Jacobsen ED, Toyama K, Goodman AM, Hendrie P, Cao XX, Estrada-Veras JI, Shpilberg O, Abdo A, Kurokawa M, Dagna L, McClain KL, Mazor RD, Picarsic J, Janku F, Go RS, Haroche J, Diamond EL. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Blood. 2020 May 28;135(22):1929-1945. doi: 10.1182/blood.2019003507. Review.</citation>
    <PMID>32187362</PMID>
  </reference>
  <reference>
    <citation>Haupt R, Minkov M, Astigarraga I, Schäfer E, Nanduri V, Jubran R, Egeler RM, Janka G, Micic D, Rodriguez-Galindo C, Van Gool S, Visser J, Weitzman S, Donadieu J; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013 Feb;60(2):175-84. doi: 10.1002/pbc.24367. Epub 2012 Oct 25.</citation>
    <PMID>23109216</PMID>
  </reference>
  <reference>
    <citation>Heitzer E. Circulating Tumor DNA for Modern Cancer Management. Clin Chem. 2019 Oct 31. pii: clinchem.2019.304774. doi: 10.1373/clinchem.2019.304774. [Epub ahead of print]</citation>
    <PMID>31672857</PMID>
  </reference>
  <reference>
    <citation>Janku F, Diamond EL, Goodman AM, Raghavan VK, Barnes TG, Kato S, Abdel-Wahab O, Durham BH, Meric-Bernstam F, Kurzrock R. Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis. Mol Cancer Ther. 2019 Jun;18(6):1149-1157. doi: 10.1158/1535-7163.MCT-18-1244. Epub 2019 Apr 23.</citation>
    <PMID>31015311</PMID>
  </reference>
  <reference>
    <citation>Murakami I, Gogusev J, Jaubert F, Matsushita M, Hayashi K, Miura I, Tanaka T, Oka T, Yoshino T. Establishment of a Langerhans cell histiocytosis lesion cell line with dermal dendritic cell characteristics. Oncol Rep. 2015 Jan;33(1):171-8. doi: 10.3892/or.2014.3567. Epub 2014 Oct 24.</citation>
    <PMID>25351656</PMID>
  </reference>
  <reference>
    <citation>Raciborska A, Bilska K, Węcławek-Tompol J, Gryniewicz-Kwiatkowska O, Hnatko-Kołacz M, Stefanowicz J, Pieczonka A, Jankowska K, Pierelejewski F, Ociepa T, Sobol-Milejska G, Muszyńska-Rosłan K, Michoń O, Badowska W, Radwańska M, Drabko K. Clinical characteristics and outcome of pediatric patients diagnosed with Langerhans cell histiocytosis in pediatric hematology and oncology centers in Poland. BMC Cancer. 2020 Sep 11;20(1):874. doi: 10.1186/s12885-020-07366-3.</citation>
    <PMID>32917181</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Mother and Child, Warsaw, Poland</investigator_affiliation>
    <investigator_full_name>Anna Raciborska</investigator_full_name>
    <investigator_title>Prof Ass</investigator_title>
  </responsible_party>
  <keyword>LCH</keyword>
  <keyword>histiocytosis</keyword>
  <keyword>PET</keyword>
  <keyword>molecular status</keyword>
  <keyword>paediatric patiens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

